On July 17, 2023, PHEN hosted a clinical trials webinar with Dr. Neal Shore, US Chief Medical Officer at GenesisCare USA, as the guest presenter. The event titled Novel Targeted Therapy for Metastatic Castration Resistant Prostate Cancer reviewed a pioneering targeted therapy known as Vobra Duo with a presentation about the Tamarack clinical trial.

The underrepresentation of African-American men in prostate cancer clinical research is a significant problem, given the disproportionately high incidence and poor prognosis in African-American men compared to other groups.

Dr. Keith Crawford, Director of Clinical Trials and Patient Education at PHEN, provided the background on Antibody Drug Conjugates (ADCs), an innovative form of targeted therapy. ADCs are monoclonal antibodies that bind to proteins found on cancer cells and deliver cancer-killing drugs.

Dr. Shore discussed the Tamarack clinical trial. This trial uses Vobramitamab duocarmazine (Vobra Duo), an ADC that targets the B7-H3 molecule highly expressed in advanced prostate cancer. The recorded clinical trials webinar is available here on PHENTV.com.

The audience consisted of 72.4% prostate cancer patients/survivors, 7% industry representatives, 10.3% spouses or caregivers, and 10.3% advocates. The poll results showcased the success and effectiveness of the webinar. 100% of attendants answered that they were satisfied with this clinical trial webinar. 93% of respondents felt the content fully met their expectations. The complete survey results are available here.